Sensex Snaps 7-Day Winning Streak, Nifty Falls Below 18,450; ITC Dips 6%

Tue, 19 Oct Closing

   Previous Close   

   Pre-Open   

   09:30 am   

   12:30 pm   

Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.

Dalal street's greatest winning streak in over ten months came to an end today when benchmark indices fell for the first time in eight sessions.

Profit booking as a consequence of in-line September quarter results pulled markets down from intra-day highs.

At the closing bell, the BSE Sensex stood lower by 50 points (down 0.1%).

Meanwhile, the NSE Nifty closed lower by 58 points (down 0.3%).

Tech Mahindra and Larsen & Toubro were among the top gainers today.

ITC and Tata Motors, on the other hand, were among the top losers today.

The SGX Nifty was trading at 18,444, down by 52 points, at the time of writing.

The BSE Mid Cap index and the BSE Small Cap index ended down by 2% and 1.8%, respectively.

Sectoral indices ended on a negative note with stocks in the realty sector, consumer durables sector and FMCG sector witnessing most of the selling pressure.

IT stocks, on the other hand, witnessed buying interest.

Shares of Cera Sanitary and Oracle Financial hit their respective 52-week highs today.

Asian stock markets ended on a positive note today.

The Hang Seng and the Shanghai Composite ended up by 1.5% and 0.7%, respectively. The Nikkei ended up by 0.7% in today's session.

US stock futures are trading on a positive note today with the Dow Futures trading up by 88 points.

The rupee is trading at 75.34 against the US$.

Gold prices for the latest contract on MCX are trading up by 0.3% at Rs 47,430 per 10 grams.

Speaking of the stock markets, Brijesh Bhatia, Research Analyst at Fast Profits Report shares his view on housing finance stocks, in his latest video for Fast Profits Daily.

Tune in to the video below to find out more:

In news from the FMCG sector, Hindustan Unilever was among the top buzzing stocks today.

Hindustan Unilever (HUL) reported a standalone net profit of Rs 21.9 bn for the September quarter, an increase of 9% from Rs 20.1 bn reported in the same quarter last year.

On a sequential basis, the profit after tax (PAT) grew 6% from Rs 20.6 bn in the June quarter.

The FMCG major's revenue from operations rose 11% to Rs 127.2 bn as against Rs 114.4 bn in the year-ago period.

HUL's domestic consumer business recorded a growth of 11% over last year during the September quarter.

Segment wise, home care business grew 15% in the reporting period, driven by high double-digit growth in Fabric Wash. Household care continued to perform well and grew on a strong base. Liquids and fabric sensations continued to outperform.

Beauty and Personal Care grew 10% led by skin care, colour cosmetics and hair care, while foods and refreshment business has seen a growth of 7% against a strong prior year comparator.

The company has also declared an interim dividend of Rs 15 per equity share for the financial year ending 31 March 2022.

Hindustan Unilever share price ended the day down by 3.7% on the BSE.

Speaking of the FMCG sector, have a look at the chart below which shows the performance of BSE Sensex and BSE FMCG index since 2009.

While the Sensex has offered more than 393% returns since 2009, the BSE FMCG index has gone up a staggering 532% returns over the same period.

Richa Agarwal, Senior Research Analyst at Equitymaster, and Editor of the smallcap service, Hidden Treasure, believes this outperformance could continue for many years.

With a rising population and standards of living, Indian's consumption demand for FMCG products will skyrocket over the coming years.

Moving on to news from the pharma sector...

Dr. Reddy's Gets Approval for Lenalidomide Capsules from USFDA

Dr. Reddy's today announced that it has received approval for Lenalidomide capsules from the US Food and Drug Administration (USFDA).

The company announced the final approval of its abbreviated new drug application (ANDA) for Lenalidomide Capsules, in 2.5 mg and 20 mg strengths, and tentative approval for 5 mg, 10 mg, 15 mg, and 25 mg strengths, a therapeutic equivalent generic version of REVLIMID (lenalidomide) capsules, from the USFDA.

With this approval, the company is eligible for 180 days of generic drug exclusivity for Lenalidomide Capsules.

Marc Kikuchi, CEO, North America Generics, Dr Reddy's Laboratories said,

• We are pleased with the agency's approval of Lenalidomide Capsules, 2.5 mg and 20 mg and being eligible for 180-day market exclusivity.
  
  We look forward to bringing a more affordable generic version of this drug to market for the benefit of patients.

In September 2020, Dr Reddy's announced a settlement agreement of their litigation with Celgene, the maker of REVLIMID (lenalidomide) capsules and a wholly-owned subsidiary of Bristol Myers Squibb, relating to patents for the branded drug.

Dr. Reddy's share price ended the day down by 1% on the BSE.

To know what's moving the Indian stock markets today, check out the most recent share market updates here.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

Read the latest Market Commentary

Top Gainers TodayTop Gainers over 1-WeekTop Gainers over 1-MonthTop Gainers over 1-YearTop Gainers over 3-YrsTop Gainers over 5-YrsTop Losers TodayTop Losers over 1-WeekTop Losers over 1-MonthTop Losers over 1-YearTop Losers over 3-YrsTop Losers over 5-YrsOnly BuyersOnly SellersMost Active StocksMost Popular Stocks52 Week High Stocks52 Week Low Stocks

INDICESBSE (Rs 0 to 1)BSE (Rs 1 to 2)BSE (Rs 2 to 4)BSE (Rs 4 to 10)BSE (Rs 10 to 20)BSE (Above Rs 20)BSE - AllBSE-30BSE-100BSE-200BSE-500BSE AutoBSE BankexBSE Capital GoodsBSE Consumer DurablesBSE FMCGBSE HealthcareBSE ITBSE MetalBSE Oil & GasBSE PSUBSE TeckBSE RealtyBSE PowerBSE A GroupBSE B GroupBSE Mid-CapBSE Small-CapBSE Basic MaterialsBSE Consumer DiscretionaryBSE IndustrialsBSE UtilitiesBSE Sensex 50BSE Sensex Next 50BSE Bharat 22BSE 150 MidCapBSE 250 SmallCapBSE 250 LargeMidCapBSE 400 MidSmallCapBSE AllCapBSE LargeCapBSE SmallCap SelectBSE 100 LargeCap TMCBSE InfraBSE ManufacturingBSE CPSEBSE Private BankBSE Diversified FinancialsBSE MomentumBSE Low VolatilityBSE QualityBSE Enhanced ValueBSE Divident StabilityS&P BSE IPOBSE SMEIPOBSE 100 ESGBSE CarbonexBSE GreenexNSE (Rs 0 to 10)NSE (Rs 10 to 20)NSE (Above Rs 20)NSE - AllNSE-50NSE ITNSE Nifty Midcap 50NSE JR. NiftyNSE Bank NiftyNIFTY Next 50NIFTY 100NIFTY 200NIFTY 500NIFTY MidCap 100NIFTY SmallCap 250NIFTY SmallCap 50NIFTY SmallCap 100NIFTY LargeMidCap 250NIFTY MidSmallCap 400NIFTY AutoNIFTY Consumer DurablesNIFTY FinanceNIFTY FMCGNIFTY MediaNIFTY MetalNIFTY PharmaNIFTY Private BankNIFTY PSU BankNIFTY RealtyNIFTY Oil & GasNIFTY SME EmergeNIFTY CommoditiesNIFTY CPSENIFTY EnergyNIFTY India ConsumptionNIFTY InfraNIFTY MNCNIFTY PSENIFTY Serv SectorNIFTY100 Liquid 15NIFTY Midcap Liquid 15NIFTY Midcap 150 Quality 50NIFTY50 Equal WeightNIFTY100 Equal WeightNIFTY100 Low Volatility 30NIFTY100 Alpha 30NIFTY Alpha 50NIFTY Dividend Opportunities 50NIFTY High Beta 50NIFTY Low Volatility 50NIFTY200 Quality 30NIFTY 500 Value 50NIFTY 100 Quality 30SECTORSAgricultureAirlinesAluminiumAsset Management CompaniesAutomobilesAuto AncillariesBanks (Private)Banks (PSU)BankingCementChemicalsDefenceDiagnosticsDronesEngineeringElectric VehicleElectric Vehicle BatteryEnergy SourcesESGEthanolFertilizersFintechFMCGFoodGreen HydrogenHotelsInfrastructureInsuranceInvestment and FinanceInvITIT (Large)IT (Others)LogisticsMediaMetalMiningIndia's Big Tech StocksIndian PharmaMNC PharmaPSUPaintPaperPlasticPowerRating AgenciesReal EstateREITsRenewable EnergyRetailingSemiconductorShippingSteelSugarSupply ChainTelecomTextilesTravel Support Services

10 results 25 results 50 results 100 results All results

Indian Share Market Update: Top Gainers and Losers